EUVIMEDEUVIMED entdecken
Leserbrief

Immunogenicity and Efficacy of Subcutaneous Infliximab Monotherapy vs Combination Therapy in IBD

Cong Dai, Yu-Hong Huang, Min Jiang

Clinical Gastroenterology and Hepatology · 2026-05 · 24 (5) · 1472-1473

DOI: 10.1016/j.cgh.2025.06.031 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-05. Verfasst von Cong Dai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, First Affiliated Hospital, China Medical University, Shenyang City, Liaoning Province, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Gastroenterology, First Affiliated Hospital, China Medical University, Shenyang City, Liaoning Province, China.

Zitieren

APA

Dai, C., Huang, Y. H., & Jiang, M. (2026). Immunogenicity and Efficacy of Subcutaneous Infliximab Monotherapy vs Combination Therapy in IBD. Clinical Gastroenterology and Hepatology, 24(5), 1472-1473. https://doi.org/10.1016/j.cgh.2025.06.031

Vancouver

Dai C, Huang YH, Jiang M. Immunogenicity and Efficacy of Subcutaneous Infliximab Monotherapy vs Combination Therapy in IBD. Clinical Gastroenterology and Hepatology. 2026;24(5):1472-1473. doi:10.1016/j.cgh.2025.06.031

BibTeX
@article{Dai2026,
  author = {Dai, Cong and Huang, Yu-Hong and Jiang, Min},
  title = {Immunogenicity and Efficacy of Subcutaneous Infliximab Monotherapy vs Combination Therapy in IBD},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  volume = {24},
  number = {5},
  pages = {1472--1473},
  doi = {10.1016/j.cgh.2025.06.031}
}
Kostenlos starten →